登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验,由北京高博医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06389305,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
1 岁 至 39 岁;性别:不限
登记记录的入选字段
A confirmed diagnosis of refractory or relapsed B-ALL (criteria reference: NCCN, 2024.4), where all patients meet the National Comprehensive Cancer Network(NCCN) guidelines for the diagnosis of acute lymphoblastic leukemia (hematopathological examination of bone marrow aspirate and biopsy tissue showing ≥20% lymphoblasts in the bone marrow, confirmed by comprehensive flow cytometry (FCM) immunotyping, minimal residual disease analysis, and G-banded metaphase chromosome karyotype analysis). Molecular characteristics can be described through methods such as interphase fluorescence in situ hybridization (FISH) testing, reverse transcription polymerase chain reaction (RT-PCR) testing, and next-generation sequencing (NGS) for comprehensive detection of fusion genes and pathogenic mutations. Determination can also be made by the World Health Organization's subtypes of acute lymphoblastic leukemia, as well as cytogenetic and clinical risk groups.
入选标准第 2 条
Loss of CAR-T cell activity within 6 months after previous CAR-T therapy and no relapse.
入选标准第 3 条
Received bendamustine treatment within the past 9 months;
排除标准第 2 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
入选标准第 6 条
Serum creatinine and/or blood urea nitrogen ≥ 1.5 times the normal value;
排除标准第 8 条
Active or uncontrollable infectious diseases, such as hepatitis (HBV, HCV), HIV, or syphilis.
排除标准第 17 条
Female patients (those with childbearing potential) are pregnant or lactating;
排除标准第 16 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06389305,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
A patient must meet all of the following to be enrolled: A confirmed diagnosis of refractory or relapsed B-ALL (criteria reference: NCCN, 2024.4), where all patients meet the National Comprehensive Cancer Network(NCCN) guidelines for the diagnosis of acute lymphoblastic leukemia (hematopathological examination of bone marrow aspirate and biopsy tissue showing ≥20% lymphoblasts in the bone marrow, confirmed by comprehensive flow cytometry (FCM) immunotyping, minimal residual disease analysis, and G-banded metaphase chromosome karyotype analysis). Molecular characteristics can be described through methods such as interphase fluorescence in situ hybridization (FISH) testing, reverse transcription polymerase chain reaction (RT-PCR) testing, and next-generation sequencing (NGS) for comprehensive detection of fusion genes and pathogenic mutations. Determination can also be made by the World Health Organization's subtypes of acute lymphoblastic leukemia, as well as cytogenetic and clinical risk groups. Loss of CAR-T cell activity within 6 months after previous CAR-T therapy and no relapse. Age between 1 and 39 years old. No severe allergic constitution. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Life expectancy, as judged by the investigator, of at least 60 days. Patients with self-awareness between 8 and 39 years of age voluntarily sign an informed consent, and the legal representative (guardians) of child patients under 18 years of age voluntarily signs an informed consent.排除标准:Exclusion Criteria:
A patient with at least one of the following conditions will be excluded: Received bendamustine treatment within the past 9 months; Intracranial hypertension or impaired consciousness in the brain; Symptomatic heart failure or severe arrhythmia; Symptoms of severe respiratory failure; With other types of malignant tumors; Disseminated intravascular coagulation; Serum creatinine and/or blood urea nitrogen ≥ 1.5 times the normal value; Suffering from sepsis or other uncontrollable infections; Uncontrollable diabetes; Severe mental disorders; Significant lesions in the brain as detected by head magnetic resonance imaging; Leukemic cells in the cerebrospinal fluid >20 cells/μL; Peripheral blood leukemic cell proportion >30%; Have undergone organ transplantation; Female patients (those with childbearing potential) are pregnant or lactating; Active or uncontrollable infectious diseases, such as hepatitis (HBV, HCV), HIV, or syphilis.
引自 ClinicalTrials.gov, NCT06389305, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06389305,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。